• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 29, 2021

View Archived Issues
IPO line graph

Four more IPOs make strides as a powerful 2021 nears its close

Entrada Therapeutics Inc. is the largest of four biopharmas making new moves on IPOs as the company upsized its offer from 7.5 million to 9.07 million shares priced at $20 each. Last year saw $22.48 billion in biopharma IPOs, a record, according to BioWorld stats. Aside from a record-setting 2020, this year’s IPO total far outpaces every other year in the past decade. With the end of 2021 in sight, there have been 110 completed global biopharma IPOs totaling $18.13 billion. Read More

FDA awards EUA to Pfizer’s COVID-19 vaccine for children

The FDA has granted emergency use authorization (EUA) to the COVID-19 vaccine created by Pfizer Inc.-Biontech SE for use in children ages 5 through 11. This is the first EUA for a COVID-19 vaccine to be awarded for this group of roughly 28 million children in the U.S. and it comes after weeks of lengthy debate among experts about the wisdom of targeting the young demographic. Read More
kidney-nephrology.png

Travere gains on positive FDA meetings over IgAN drug; rival Calliditas crashes

It’s all systems “go” for Travere Therapeutics Inc. and its sparsentan after meetings with the FDA paved the way for filings and potential accelerated approvals in the rare kidney disease IgA nephropathy and the kidney scarring condition focal segmental glomerulosclerosis. Read More

Travere, Aeglea to face off in HCU; no likely winner clear yet

Travere Therapeutics Inc.’s mid-September deal with Vifor Pharma Group – a collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand – brought further, well-deserved attention to the dual endothelin angiotensin receptor antagonist, in the works for rare kidney disorders, specifically focal segmental glomerulosclerosis and IgA nephropathy. Read More
Oral medication

Shouti raises $100M in series B round to turn injectable medicines into pills

Shouti Inc. raised $100 million in a series B round led by BVF Partners LP to advance its discovery platform for designing oral medicines and to speed up the development of its candidates. The Shanghai and California-based company has secured a total of $158 million in funding so far. Read More
coronavirus money

COVID-19 still accounts for bulk of nonprofit deals and grants

On target with last year, a total of 87% of funds recorded in 2021 through biopharma collaborations with nonprofit entities by the end of October are focused on COVID-19 pandemic efforts. The pandemic accounts for 54% of the money collected through grants, which is still a sturdy amount but down from 76% in 2020. Read More

Appointments and advancements for Oct. 29, 2021

New hires and promotions in the biopharma industry, including: AC Immune, Biogen Canada, Kinnate, Werewolf. Read More

Financings for Oct. 29, 2021

Biopharmas raising money in public or private financings, including: 4D, Armata, Innoviva, Pascal, Signet, Valneva. Read More

In the clinic for Oct. 29, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Alnylam, Alphamab, Alzinova, Arca, Candel, Context, Edgewise, Hutchmed, Immunic, Inventiva, Landos, Meissa, Optinose, Rafael, Paxmedica, Revolo, Sorrento, Talaris. Read More

Other news to note for Oct. 29, 2021

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aivita, Awakn, Biontech, Bridgebio, Curacle, Eton, Gilead, Innovent, Merck, Neocura, Pfizer, Polyphor, PF Argentum, Trillium. Read More

Regulatory actions for Oct. 29, 2021

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: ADC, Akebia, Boehringer, Cytodyn, HCW, Huya, Immunoforge, Immutep, Impact, Kite, Neuroene, Novavax, Oramed, Pfizer, RDIF, Reata, Regeneron, Sanofi, Spero, TFF, Vertex, Viiv. Read More

Money raised by biopharma: 2021 vs. 2020 vs. 2019

Total raised in public, private and other financings of biopharma companies, comparing 2021 vs. 2020 vs. 2019. Read More

Biopharma money raised: Jan. 1-Oct. 28, 2021

Year-to-date money raised in public, private and other financings of biopharma companies. Read More
stock prices up

Biggest gainers and losers for the week of Oct. 25-29, 2021

The top 10 biopharma stock gainers and losers for the week. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • Scientists shaking hands in the lab

    Illumina buying Somalogic for up to $425M to boost multiomics assets

    BioWorld MedTech
    In a bid to boost its multiomics holdings, Illumina Inc. reported an agreement to buy proteomics technology company Somalogic Inc. from Standard Biotools Inc. for...
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    Otsuka licenses Harbour’s bispecific T-cell engager for $670M

    BioWorld
    Harbour Biomed is out-licensing its B-cell maturation antigen and CD3 bispecific T-cell engager HBM-7020 for autoimmune diseases to Otsuka Pharmaceutical Co. Ltd....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe